Home › Chronic Myeloid Leukemia › NCT06229860

Impact of Personality on Adherence to Tyrosine Kinase Inhibitor Therapy in Pts w/Chronic Myeloid Leukemia

Impact of Personality on Adherence to Tyrosine Kinase Inhibitor Therapy in Patients With Chronic Myeloid Leukemia

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* 18 years of age or older
* Diagnosed with chronic myeloid leukemia (CML) and in the chronic phase (CML-CP)
* Currently being treated with one of four cancer medications - imatinib, dasatinib, bosutinib, or nilotinib
* A patient at the UCI Chao Family Comprehensive Cancer Center (CFCCC), or
* A member of a patient support group organized by the CML Buster Foundation
* Do not meet any of the criteria listed under "Exclusion Requirements"

Exclusion Criteria:

* Unable to read and speak English
* Impaired decisional capacity to consent

About the study

This is an observational pilot study to examine the association between a patient's personality and adherence to tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.

What is being tested

• Interview (other)

Sponsor: University of California, Irvine · Participants: 75 · Started: Jan 25, 2024

Contact the study team

• Chao Family Comprehensive Cancer Center University of California, Irvine · Phone: 1-877-827-8839

Official record on ClinicalTrials.gov — NCT06229860

Locations in the U.S.

Conditions

• Chronic Myeloid Leukemia
• Chronic-Phase Myeloid Leukemia

From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.